Arch Biopartners closes $600,000 private placement

Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) closed a non-brokered private placement offering of 576,923 common shares at $1.04 per share for gross proceeds of $600,000 CAD, according to a company statement.

The final amount represented an increase of $100,000 CAD from the amount originally disclosed on November 10, 2025. The company plans to use proceeds as general working capital and for operating expenses not covered by human trial funding grants.

The offering included 480,923 common shares issued to a company officer, constituting a related party transaction under Multilateral Instrument 61-101. The transaction is exempt from formal valuation and minority shareholder approval requirements since the fair market value does not exceed 25% of the company's market capitalization.

All shares issued are subject to a hold period of four months and one day from the closing date. No finders' fees were paid in connection with the offering.

The offering remains subject to regulatory approvals, including final approval from the TSX Venture Exchange.

Arch Biopartners develops treatments for acute kidney injury and chronic kidney diseases. The company's pipeline includes LSALT peptide in Phase II trials for cardiac surgery-associated acute kidney injury and cilastatin in Phase II trials for toxin-induced acute kidney injury, along with a pre-clinical chronic kidney disease program.

The company has 66,933,289 common shares outstanding.

You May Also Be Interested In